News

Early mitochondrial stress reveals potential mechanism for lasting heart protection

Mitochondria are popularly known as the "powerhouse of the cell," but these cellular structures do much more—including acting as signaling hubs. Some signals that mitochondria send can reprogram the activity of the entire cell by switching "on" or "off" different genes through epigenetic changes. Mitochondria's signals can be so effective that, in yeast, fruit flies and worms, mild stress in mitochondria early in life can make the entire organism more resilient and live longer through a process called mitohormesis.

Scribe Therapeutics starts first human trial for cholesterol-lowering gene therapy

Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress. The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis Society showing up to 90% PCSK9 silencing and LDL-C reductions up to 68%, with a 0.75 […] The post Scribe Therapeutics starts first human trial for cholesterol-lowering gene therapy appeared first on Longevity.Technology.

‘If you can’t understand what sex is, it’s irrelevant if you seem to be enjoying it’: how Queen at Sea upended the dementia drama

Lance Hammer’s first film in 18 years is a heart-wrenching masterpiece about family, mental decline and sexual consent. He and supporting actor Juliette Binoche discuss how they brought unabashed realism to a condition rarely seen on screen The first time we see Martin and Leslie, the elderly couple at the centre of Lance Hammer’s wrenching new film, Queen at Sea, they are walking together up a set of stone steps: one of their regular outings, we assume, in days filled with pottering and quiet companionship. They have their backs to us, and we can’t see their destination beyond a bleached sky that fills the top half of the screen. Symbolically, it may be deemed a bit on the nose: two people near the end of their lives, moving gently towards the white light of oblivion. There’s a whiff of sentimentality about it. But any doubts about this story’s willingness to confront dif

Immune System Signatures Correlate with the Near Term Risk of Developing Atherosclerosis

Atherosclerosis is universal; everyone develops fatty atherosclerotic plaques in their arteries at some point, and to some degree. Plaques narrow blood vessels to impede blood flow, and rupture of unstable plaque causes heart attack, stroke, and embolism. It is the largest cause of human mortality, and at present the best that the medical community can do is to slow down plaque growth. Established therapies based on reducing the amount of cholesterol carried outward from the liver on low-density lipoprotein (LDL) particles produce something like a 15% mortality risk reduction at best, and do not regress plaque to any meaningful degree. Interestingly, the drivers of atherosclerosis are sufficiently complex and varied for there to be a few lucky people who exhibit 10% or more plaque regression […]

United Therapeutics presents positive Phase 3 lung disease study data

United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona. Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population […] The post United Therapeutics presents positive Phase 3 lung disease study data appeared first on Longevity.Technology.

Greenstone bets on human cells to fix DMD hearts

Fresh NIH funding backs an iPSC-and-AI push to find drugs for Duchenne cardiomyopathy without relying on mouse models that rarely translate. By the numbers, the translational gap is expensive. Roughly nine in ten drug candidates that succeed in animal models still fail once they reach human trials, and cardiology has one of the worst records […] The post Greenstone bets on human cells to fix DMD hearts appeared first on Longevity.Technology.

Children of centenarians often live longer and face lower cardiovascular risks, analysis finds

Adults with at least one parent who reached age 100 lived longer and had substantially lower risks of cardiovascular disease and hypertension than people whose parents had shorter lifespans, according to a study published today in JAMA Network Open.

Short, Intense Exercise Elicits Beneficial Metabolic Changes

A new study compared high-intensity sprint-interval exercise with moderate-intensity exercise. The former produced larger changes in circulating protein and metabolite levels than the latter and stimulated proteins associated with cardiometabolic health benefits [1]. Short and intense vs. […]

Alnylam showcases late-breaking heart treatment, hypertension findings at ESC 2026

Alnylam will present new clinical and real-world data across its transthyretin-mediated amyloidosis and hypertension programs at ESC Congress 2026 in Munich on 28-31 August 2026. Presentations include late-breaking pre-specified analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) assessing outcomes in patients on background stabilizer therapy, additional HELIOS-B analyses of healthy aging, functional capacity, […] The post Alnylam showcases late-breaking heart treatment, hypertension findings at ESC 2026 appeared first on Longevity.Technology.

When you eat may matter as much as what you eat for longevity and heart health

What we eat plays a vital role in maintaining a healthy lifestyle. A well-balanced meal rich in essential micronutrients not only fuels the body but may also help protect against metabolic and cardiovascular diseases. There is another question worth asking: Does when we eat matter just as much as what we eat?

Too much or too little sleep may make your body age faster

Both too little and too much sleep may be linked to faster aging throughout the body. Researchers analyzing 23 biological aging clocks found the lowest aging levels among people sleeping about 6.4 to 7.8 hours per day. Short or long sleep was also associated with numerous conditions affecting the brain, heart, lungs, metabolism, and digestive system.

The association between mobility and asleep blood pressure alterations in frail and non-frail adults 80 years and older

A little-known protein may be fueling Alzheimer’s — and scientists found a way to block it

An experimental Alzheimer’s compound prevented damaging protein clumps from forming in the brains of mice, helping nerve cells survive longer and reducing amyloid buildup. The treatment also appeared to improve heart health and slow some signs of aging, raising hopes for an entirely new way to combat dementia.

ZEUS does not end inflammation drug discovery – it raises the bar

Novo’s ziltivekimab failure challenges the “lower hsCRP, improve outcomes” thesis – DLT data point to NLRP3 and senescent-cell biology next. Novo Nordisk’s phase 3 ZEUS failure has shaken the cardiovascular inflammation field. Ziltivekimab was designed to block interleukin-6, a cytokine associated with residual inflammatory risk in patients with cardiovascular disease. In ZEUS, the drug produced […] The post ZEUS does not end inflammation drug discovery – it raises the bar appeared first on Longevity.Technology.

BioCardia advances heart failure therapy toward regulatory approval steps in U.S. and Japan

BioCardia reported second quarter 2026 financial results and filed its Form 10-Q for the quarter ended 30 June 2026, according to the company. Japan’s Pharmaceutical and Medical Device Agency provided a Consultation Record supporting a Shonin pre-market submission for CardiAMP in ischemic heart failure with reduced ejection fraction while requesting confirmation that enrolled patients received […] The post BioCardia advances heart failure therapy toward regulatory approval steps in U.S. and Japan appeared first on Longevity.Technology.

Greenstone receives NIH R61 grant for cardiac fibrosis

Greenstone Biosciences has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to fund the discovery of drug candidates targeting myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy. The R61 phase will support target identification and early candidate discovery with a possible R33 […] The post Greenstone receives NIH R61 grant for cardiac fibrosis appeared first on Longevity.Technology.

For decades, we were told to choose low-fat dairy. New research says otherwise

Full-fat dairy may be healthier than conventional advice has suggested. In a 12-week study, adults who ate three servings a day showed no meaningful increases in weight, body fat, cholesterol, or insulin resistance. They also experienced improved blood pressure and consumed more calcium, protein, and vitamin D. The findings suggest dairy’s complex structure may matter more than its saturated fat content alone.

HAYA’s FDA fast-track win puts heart aging in focus

FDA designation signals growing interest in therapies that aim to reprogram diseased cells rather than just managing heart disease symptoms. What if scar tissue in the heart wasn’t permanent? What if the cells responsible for creating that damage could simply be persuaded to behave differently? Those questions sit at the center of one of longevity […] The post HAYA’s FDA fast-track win puts heart aging in focus appeared first on Longevity.Technology.

Nearly half of dementia cases may be linked to risks you can change

A long-term brain study found that common risks such as smoking, high blood pressure, heart disease, and high blood lipids were strongly linked to damage associated with vascular dementia. The findings suggest that healthier lifestyle choices could help delay dementia by reducing several harmful brain changes at once.

HAYA Therapeutics earns FDA Fast Track designation for novel heart disease therapy

HAYA Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy. HTX-001 is an investigational antisense oligonucleotide that the company describes as first-in-class and engineered to downregulate WISPER, a heart stress-specific long non-coding RNA, with the intent of reprogramming fibrotic cardiac myofibroblasts […] The post HAYA Therapeutics earns FDA Fast Track designation for novel heart disease therapy appeared first on Longevity.Technology.

Longevity AI, Clalit collaborate to improve heart disease and diabetes risk predictions

Longevity AI and researchers from Meir Medical Center of the Clalit Health Group announced a joint research collaboration to evaluate and recalibrate clinical risk prediction models for cardiovascular disease and Type 2 diabetes using longitudinal real-world data from Clalit’s integrated healthcare system. The initiative will retrain and assess globally recognized cardiovascular and Type 2 diabetes […] The post Longevity AI, Clalit collaborate to improve heart disease and diabetes risk predictions appeared first on Longevity.Technology.

Hilo aims to make blood pressure a daily habit

Swiss-developed system brings longitudinal blood pressure monitoring to the US, reflecting broader shift toward continuous preventive health. Blood pressure is one of medicine’s oldest biomarkers; it is also one of its most neglected. While cardiovascular risk accumulates over decades, measurement often remains confined to fleeting moments – a hurried clinic appointment, an annual health check […] The post Hilo aims to make blood pressure a daily habit appeared first on Longevity.Technology.

Mediterranean diet may activate tiny proteins that protect the heart and brain

The Mediterranean diet may influence aging through tiny proteins produced inside the cell’s mitochondria. Older adults who followed the diet most closely had higher levels of humanin and SHMOOSE, which have been linked to heart and brain protection. Olive oil, fish, legumes, and fewer refined carbohydrates appeared especially important. The findings could eventually help scientists develop more personalized nutrition plans for healthy aging.

This drug could help millions keep their kidneys working longer

An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and cardiovascular complications in people with chronic kidney disease who do not have diabetes. The results could open the door to a much-needed new treatment option for the majority of CKD patients who have long had limited choices.

BioAge doses first patient in Phase 2 trial of new cardiovascular drug

BioAge Labs has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 proof-of-concept trial of BGE-102, according to the company. BGE-102 is described as a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen’s DEL technology and being advanced as a once-daily oral […] The post BioAge doses first patient in Phase 2 trial of new cardiovascular drug appeared first on Longevity.Technology.